Effects of late conversion to everolimus and calcineurin inhibitor dosage reduction on graft function in renal transplant patients

Trial Profile

Effects of late conversion to everolimus and calcineurin inhibitor dosage reduction on graft function in renal transplant patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2015 New trial record
    • 16 Sep 2015 Results presented at 17th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top